CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-23 | Nguyen Diem Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Gaeta Renee Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Benz Edward J. JR Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-03-31 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +779 | $4.11 | $3K | 779 |
| 2026-03-31 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +4,618 | $4.11 | $19K | 4,618 |
| 2026-03-31 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +2,795 | $4.11 | $11K | 2,795 |
| 2026-02-23 | Manning Paul B Director | Purchase | +550,458 | $5.45 | $3.0M | 2,763,527 |
| 2026-01-26 | Tyagarajan Seshu Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +154,000 | 154,000 | ||
| 2026-01-26 | Nichols William Garrett Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +136,500 | 136,500 | ||
| 2026-01-26 | Schoch Charles Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +232,000 | 232,000 | ||
| 2026-01-26 | Tak Paul Peter Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +629,000 | 629,000 | ||
| 2026-01-26 | Barone Francesca Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +232,000 | 232,000 | ||
| 2025-07-28 | Nichols William Garrett Chief Medical Officer | Option exercise 10b5-1 | +937 | $1.29 | $1K | 53,430 |
| 2025-07-28 | Nichols William Garrett Chief Medical Officer | Sale 10b5-1 | −937 | $6.98 | $7K | 52,493 |
| 2025-07-28 | Nichols William Garrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −937 | 29,377 | ||
| 2025-06-30 | Nichols William Garrett Chief Medical Officer | Option exercise 10b5-1 | +781 | $1.29 | $1K | 53,274 |
| 2025-06-30 | Nichols William Garrett Chief Medical Officer | Sale 10b5-1 | −781 | $5.04 | $4K | 52,493 |
| 2025-06-30 | Nichols William Garrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −781 | 30,314 |
Page 2 of 13 · 249 trades